Catalyst Pharmaceuticals (CPRX) Net Cash Flow (2010 - 2026)

Catalyst Pharmaceuticals (CPRX) has 17 years of Net Cash Flow data on file, last reported at $46.7 million in Q1 2026.

• For the quarter ending Q1 2026, Net Cash Flow fell 26.01% year-over-year to $46.7 million; the trailing twelve-month figure through Mar 2026 stood at $175.2 million (down 35.17% YoY), and the FY2025 full-year result was $191.6 million, down 49.56% from the prior year.
• Net Cash Flow for Q1 2026 stood at $46.7 million, up from $19.3 million in the prior quarter.
• Across five years, Net Cash Flow topped out at $172.8 million in Q1 2024 and bottomed at -$150.1 million in Q1 2023.
• The 5-year median for Net Cash Flow is $42.3 million (2022), against an average of $33.8 million.
• The widest annual swing landed in 2023, when Net Cash Flow sank 2267.58%; it then surged 351.38% in 2024.
• A 5-year view of Net Cash Flow shows it stood at $42.3 million in 2022, then plunged by 60.63% to $16.7 million in 2023, then soared by 351.38% to $75.2 million in 2024, then sank by 74.37% to $19.3 million in 2025, then soared by 142.17% to $46.7 million in 2026.
• The last three Net Cash Flow figures came in at $46.7 million (Q1 2026), $19.3 million (Q4 2025), and $37.1 million (Q3 2025), per Business Quant data.

Peer Comparison